Chronic kidney disease Urological and Genital Diseases
Conditions
Interventions
Using an established VA dashboard that identifies chronic kidney disease patients that are candidates for SGLT2i therapy, half of eligible patients will be sent a letter informing them of the benefits
Sponsors
Minneapolis VA Health Care System
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. CKD (defined as eGFR >=25 and eGFR =7) 3. Must have active Metformin or (not on Metformin and has a Metformin allergy)
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes 2. Taking SGLT-2 or GLP-1 3. SGLT2 allergy 4. On dialysis 5. Have a diagnosis of Pancreatic Cancer or Pancreatitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SGLT2i initiation will be tracked quarterly by assessing the presence of SGLT2 inhibitors on active medication lists in the electronic health record | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Reach: Proportion of eligible patients being reached in each intervention assessed quarterly by data collected through the tracking app that has been developed to monitor patient outreach 2. Fidelity: Measured using an intervention tracking app assessed quarterly by data collected through the tracking app that has been developed to monitor patient outreach 3. Acceptability: Patient perception of starting the medication will be measured at the end of year one and the end of year two through semi-structured one-on-one qualitative interviews with patients | — |
Countries
United States of America
Contacts
Public ContactAreef Ishani
Outcome results
None listed